| 21.42 -3.66 (-14.59%) | 02-20 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 30.68 | 1-year : | 35.83 |
| Resists | First : | 26.27 | Second : | 30.68 |
| Pivot price | 20.43  |
|||
| Supports | First : | 18.25 | Second : | 13.3 |
| MAs | MA(5) : | 23.72 |
MA(20) : | 18.87 |
| MA(100) : | 16.11 |
MA(250) : | 16.24 |
|
| MACD | MACD : | 2.5 |
Signal : | 2.1 |
| %K %D | K(14,3) : | 82.2 |
D(3) : | 84.4 |
| RSI | RSI(14): 57 |
|||
| 52-week | High : | 26.27 | Low : | 12.56 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PLSE ] has closed below upper band by 44.7%. Bollinger Bands are 350.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 24.45 - 24.61 | 24.61 - 24.75 |
| Low: | 20.81 - 20.95 | 20.95 - 21.07 |
| Close: | 21.21 - 21.44 | 21.44 - 21.63 |
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Sat, 21 Feb 2026
Pulse Biosciences (NASDAQ:PLSE) Rating Increased to Hold at Wall Street Zen - MarketBeat
Fri, 20 Feb 2026
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Fri, 20 Feb 2026
Pulse Biosciences Inc (PLSE) Shares Gap Down to $22.02 on Feb 20 - GuruFocus
Fri, 20 Feb 2026
Pulse Biosciences stock slips despite Q4 beat (PLSE:NASDAQ) - Seeking Alpha
Thu, 19 Feb 2026
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2025 Financial Results - BioSpace
Thu, 19 Feb 2026
Pulse Biosciences, Inc (PLSE) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 0 (M) |
| Shares Float | 68 (M) |
| Held by Insiders | 1.757e+007 (%) |
| Held by Institutions | 73.9 (%) |
| Shares Short | 2,590 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.785e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -23 % |
| Return on Assets (ttm) | 682.5 % |
| Return on Equity (ttm) | -49 % |
| Qtrly Rev. Growth | 86000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -51.48 |
| EBITDA (p.s.) | -114201 |
| Qtrly Earnings Growth | -1.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -49 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.42 |
| Price to Cash Flow | 26.42 |
| Dividend | 0 |
| Forward Dividend | 2.57e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|